Lpath (LPTN) Upward Path Session; Great Basin Scientific (GBSN) Bullish Revenue Projections


The price of Lpath Inc. (Nasdaq:LPTN) stock soared to touch the $0.26 mark in intraday trading Thursday, finally closing at $0.25, up $0.06 (or +31.58%), and 2,451,396 of its shares were traded during the day, representing a very-large increase in activity versus its average volume (3m) of 199,203.

There appears to be no relevant recent information in the street from the company that may explain the stock’s rally. However, on February 01, 2016 the company said that complete pharmacokinetic and safety follow up data from a first-in-human study evaluating its humanized monoclonal antibody Lpathomab are anticipated to be available this month. Lpathomab is intended to treat neuropathic pain

Lpath, which is focused on bioactive signaling lipids as targets for treating and diagnosing important human diseases, has 33.14M Shares Outstanding, Market Capitalization (intraday) of $8.28M and LPTN stock 52-week range is between $0.14 and $2.38 per share



Shares of Great Basin Scientific, Inc. (Nasdaq:GBSN) skyrocketed more than 35% in the extended session Thursday after the company said that its first quarter 2016 results will show its revenue climbed 59.4% to $731,422 compared to the same period the prior year

GBSN stock closed at $2.73, down $0.40 (or -12.78%), and 1,017,261 of its shares exchanged hands during the day.

Great Basin Scientific, a molecular diagnostics company, has 3.26M Shares Outstanding and Market Capitalization (intraday) of $8.91M. GBSN stock touched a new 52-week low of $2.52 during Thursday’s market activity


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/